Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients

Multiple Sclerosis

Volumn 21, Issue 6, 2015, Pages 675-676

  De Stefano, Nicola ^a   Arnold, Douglas L ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; NATALIZUMAB; IMMUNOLOGIC FACTOR;

BRAIN ATROPHY; BRAIN SIZE; EDITORIAL; GRAY MATTER; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOATROPHY; WHITE MATTER; BRAIN; DISEASE COURSE; PATHOLOGY;

BRAIN; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; NATALIZUMAB;

EID: 84930511312     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514564494     Document Type: Editorial

References (10)

1. Filippi M, Rocca MA, Barkhof F, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012 ; 11: 349-360
2. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 2000 ; 157: 267-276
3. De Stefano N, Airas L, Grigoriadis N, et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs. 2014 ; 28: 147-156
4. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008 ; 71: 136-144
5. Chen JT, Collins DL, Atkins HL, et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology. 2006 ; 66: 1935-1937
6. Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014 ; 75: 43-49
7. Sastre-Garriga J, Tur C, Pareto D, et al. Brain atrophy in natalizumab-treated patients: A 3-year follow-up. Mult Scler. 2014 ;:
8. Paolillo A, Piattella MC, Pantano P, et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: A monthly MRI study after triple-dose gadolinium-DTPA. J Neurol. 2004 ; 251: 432-439
9. Vidal-Jordana A, Sastre-Garriga J, Perez-Miralles F, et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler. 2013 ; 19: 1175-1181
10. Nakamura K, Brown RA, Araujo D, et al. Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: Implications for monitoring atrophy in clinical studies. Neuroimage Clin. 2014 ; 6: 166-170